Viewing Study NCT01454934


Ignite Creation Date: 2025-12-25 @ 2:18 AM
Ignite Modification Date: 2025-12-28 @ 12:14 AM
Study NCT ID: NCT01454934
Status: COMPLETED
Last Update Posted: 2023-06-22
First Post: 2011-10-13
Is NOT Gene Therapy: True
Has Adverse Events: True

Brief Title: A Randomized, Open-label, Multicenter, Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Treatment of Physician's Choice in Subjects With Advanced Non-Small Cell Lung Cancer
Sponsor: Eisai Inc.
Organization: